Neurohumoral effects of orphanin FQ/nociceptin: Relevance to cardiovascular and renal function

Peptides

Volumn 21, Issue 7, 2000, Pages 1081-1099

  Kapusta, Daniel R ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Anesthesia; Anesthetized Sprague Dawley rats; Antidiuretic hormone; Autonomic nervous system; Baroreflex; Blood pressure; Central nervous system; Conscious; Endorphins; Heart rate; Hormone; Hypertension; Intracerebroventricular; Intravenous; Kidney; Mice; Microinjection; Neurotransmission; Nociceptin; Opioids; ORL1; Orphanin FQ; Parasympathetic; Renal function; Renal hemodynamics; Renal nerves; Rostral ventrolateral medulla; Sheep; Sympathetic; Vagus; Vasculature; Vasopressin

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; CLONIDINE; DERMORPHIN; ENDORPHIN; GUANABENZ; HYPOPHYSIS HORMONE; NOCICEPTIN; NOCICEPTIN RECEPTOR; OPIATE PEPTIDE; OXYTOCIN; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AUTONOMIC NERVOUS SYSTEM; BLADDER CONTRACTION; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; CENTRAL NERVOUS SYSTEM; ELECTROPHYSIOLOGY; HEART RATE; HORMONE RELEASE; KIDNEY FUNCTION; KIDNEY NERVE; MOUSE; NEUROTRANSMITTER RELEASE; NONHUMAN; PARASYMPATHETIC NERVE; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; REVIEW; SYMPATHETIC NERVE; TISSUE DISTRIBUTION; VASCULAR SMOOTH MUSCLE;

OVIS ARIES;

EID: 0033811694     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(00)00246-1     Document Type: Article

References (121)

1. 2+ channel current in rat sensory neurons by G-protein-independent mechanisms. J Neurosci. 17:1997;8721-8728.
2. Anton B., Fein J., To T., Li X., Silberstein L., Evans C.J. Immunohistochemical localization of ORL-1 in the central nervous system of the rat. J Comp Neurol. 368:1996;229-251.
3. 125I-Tyr14-orphanin FQ with the orphanin FQ receptor Kinetics and modulation by cations and guanine nucleotides . Mol Pharmacol. 51:1997;816-824.
4. ca channel activation. Brain Res. 835:1999;315-323.
5. Arndt M.L., Wu D., Soong Y., Szeto H.H. Nociceptin/orphanin FQ increases blood pressure and heart rate via sympathetic activation in sheep. Peptides. 20:1999;465-470.
6. Baerwolff M., Bie P. Effects of subpicomolar changes in vasopressin on urinary concentration. Am J Physiol. 255:1988;R940-R945.
7. Barraclough C.A., Sawyer C.H. Inhibition of the release of pituitary ovulating hormone in the rat by morphine. Endocrinology. 57:1955;329-337.
8. Bicknell R.J., Chapman C., Leng G. Effects of opioid agonists and antagonists on oxytocin and vasopressin release in vitro. Neuroendocrinology. 41:1985;142-148.
9. Bigoni R., Giuliani S., Calo' G., et al. Characterization of nociceptin receptors in the periphery in vitro and in vivo studies . Naunyn-Schmiedeberg's Arch Pharmacol. 359:1999;160-167.
10. Boom A., Mollereau C., Meunier J.C., et al. Distribution of the nociceptin and nocistatin precursor transcript in the mouse central nervous system. Neuroscience. 91:1999;991-1007.
11. Brooks D.P., Giardina G., Gellai M. Opiate receptors within the blood-brain barrier mediate kappa agonist-induced water diuresis. J Pharmacol Exp Ther. 266:1993;164-171.
12. Bucher B. ORL1 receptor-mediated inhibition by nociceptin of noradrenaline release from perivascular sympathetic nerve endings of the rat tail artery. Naunyn-Schmiedeberg's Arch Pharmacol. 358:1998;682-685.
13. Bunzow J.R., Saez C., Mortrud M., et al. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a μ, δ, or κ opioid receptor type. FEBS Lett. 347:1994;284-288.
14. Calo' G., Guerrini R., Bigoni R., et al. Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J Med Chem. 41:1998;3360-3366.
15. Calo' G., Rizzi A., Bodin M., et al. Pharmacological characterization of nociceptin receptor an in vitro study . Can J Physiol Pharmacol. 75:1997;713-718.
16. Carter D.A., Lightman S. Inhibition of vasopressin secretion by a κ-opioid receptor agonist. Neuroendocrinol Lett. 6:1984;95-100.
17. Champion H.C., Kadowitz P.J. Nociceptin, an endogenous ligand for the ORL1 receptor, has novel hypotensive activity in the rat. Life Sci. 60:1997;PL241-PL245.
18. 1]-Nociceptin has naloxone-insensitive vasodilator activity in the hindquarters vascular bed of the rat. Life Sci. 61:1997;PL403-PL408.
19. Champion H.C., Czapla M.A., Kadowitz P.J. Nociceptin, an endogenous ligand for the ORL1 receptor, decreases cardiac output and total peripheral resistance in the rat. Peptides. 18:1997;729-732.
20. Champion H.C., Pierce R.L., Kadowitz P.J. Nociceptin, a novel endogenous ligand for the ORL1 receptor, dilates isolated resistance arteries from the rat. Regul Pept. 78:1998;69-74.
21. Chen Y., Fan Y., Liu J., et al. Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. FEBS Lett. 347:1994;279-283.
22. 2 vasopressin receptor. Am J Physiol. 269:1995;F78-F85.
23. Chu X., Xu N., Li P., Wang J.Q. Profound inhibition of cardiomotor neurons in the rat rostral ventrolateral medulla by nociceptin (orphanin FQ). NeuroReport. 9:1998;1081-1084.
24. Chu X., Xu N., Li P., Wang J.Q. The nociceptin receptor-mediated inhibition of the rat rostral ventrolateral medulla neurons in vitro. Eur J Pharmacol. 364:1999;49-53.
25. Chu X., Xu N., Li P., Mao L., Wang J.Q. Inhibition of cardiovascular activity following microinjection of novel opioid-like neuropeptide nociceptin (orphanin FQ) into the rat rosteral ventrolateral medulla. Brain Res. 829:1999;134-142.
26. Civelli O., Nothacker H.-P., Bourson A., Ardati A., Monsma F., Reinscheid R. Orphan receptors and their natural ligands. J Recept Signal Transduct Res. 17:1997;545-550.
27. 2+channel currents of acutely dissociated rat periaqueductal grey neurons. J Physiol (London). 509:1998;47-58.
28. Connor M., Vaughan C.W., Chieng B., Christie M.J. Nociceptin receptor coupling to potassium conductance in locus coeruleus neurons in vitro. Br J Pharmacol. 119:1996;1614-1618.
29. 2+ in the SH-SY5Y human neuroblastoma cell line. Br J Pharmacol. 118:1996;205-207.
30. Czapla M.A., Champion H.C., Kadowitz P.J. Nociceptin, an endogenous ligand for the ORL1 receptor, has vasodilator activity in the hindquarters vascular bed of the rat. Peptides. 18:1997;793-795.
31. Czapla M.A., Champion H.C., Kadowitz P.J. Decreases in systemic arterial and hindquarters perfusion pressure in response to nociceptin are not inhibited by naloxone in the rat. Peptides. 18:1997;1197-1200.
32. DeBodo R.C. The antidiuretic action of morphine and its mechanism. J Pharmacol Exp Ther. 82:1944;74-85.
33. 2-adrenoceptors in the bradycardiac effects of clonidine and analogues. Naunyn-Schmiedeberg's Arch Pharmacol. 317:1981;8-12.
34. Doi N., Dutia M.B., Brown C.H., Leng G., Russell J.A. Inhibitory actions of nociceptin (orphanin FQ) on rat supraoptic nucleus oxytocin and vasopressin neurons in vitro. Adv Exp Med Biol. 449:1998;147-151.
35. Doi N., Dutia M.B., Russell J.A. Inhibition of rat oxytocin and vasopressin supraoptic nucleus neurons by nociceptin in vitro. Neuroscience. 84:1998;913-921.
36. Duggan A.W., North A.R. Electrophysiology of opioids. Pharmacol Rev. 35:1984;219-332.
37. Dun N.J., Dun S.L., Hwang L.L. Nociceptin-like immunoreactivity in autonomic nuclei of the rat spinal cord. Neurosci Lett. 234:1997;95-98.
38. Emmerson P.J., Miller R.J. Pre- and postsynaptic actions of opioid and orphan opioid agonists in the rat arcuate nucleus and ventromedial hypothalamus in vitro. J Physiol (London). 517:1999;431-435.
39. Faber E.S., Chambers J.P., Evans R.H., Henderson G. Depression of glutamatergic transmission by nociceptin in the neonatal rat hemisected spinal cord preparation in vitro. Br J Pharmacol. 119:1996;189-190.
40. Fischer A., Forsmann W.G., Undem B.J. Nociceptin-induced inhibition of tachykinergic neurotransmission in guinea pig bronchus. J Pharmacol Exp Ther. 285:1998;902-907.
41. Flores O., Camera L.A., Hergueta A., et al. Role of atrial natriuretic factor, hemodynamic changes and renal nerves in the renal effects of intraperitoneal (i. p.) morphine in conscious rats. Kidney Blood Press Res. 20:1997;18-24.
42. Fukuda K., Kato S., Mori K., et al. cDNA cloning and regional distribution of a novel member of the opioid receptor family. FEBS Lett. 343:1994;42-46.
43. Gintzler A.R., Adapa I.D., Toll L., Medina V.M., Wang L. Modulation of enkephalin release by nociceptin. Eur J Pharmacol. 325:1997;29-34.
44. Giuliani S., Lecci A., Tramontana M., Maggi C.A. The inhibitory effect of nociceptin on the micturation reflex in anaesthetized rats. Br J Pharmacol. 124:1998;1566-1572.
45. Giuliani S., Lecci A., Tramontana M., Maggi C.A. Nociceptin protects capsaicin-sensitive afferent fibers in the rat urinary bladder from desensitization. Naunyn-Schmiedeberg's Arch Pharmacol. 360:1999;202-208.
46. Giuliani S., Maggi C.A. Inhibition of tachykinin release from peripheral endings of sensory nerves by nociceptin, a novel opioid peptide. Br J Pharmacol. 118:1996;1567-1569.
47. Giuliani S., Maggi C.A. Prejunctional modulation by nociceptin of nerve-mediated inotropic responses in guinea-pig left atrium. Eur J Pharmacol. 332:1997;231-236.
48. Giuliani S., Tramontana M., Lecci A., Maggi C.A. Effect of nociceptin on heart rate and blood pressure in unanesthetized rats. Eur J Pharmacol. 333:1997;177-179.
49. Guerrini R., Calo G., Rizzi A., et al. A new selective antagonist of the nociceptin receptor. Br J Pharmacol. 123:1998;163-165.
50. 1) receptors possesses systemic vasorelaxant properties. Life Sci. 60:1997;PL141-PL145.
51. Haaf J.A.T., Maigret C., Andringa-Bakker E.A.D., van Wimersma Greidanus T.B. Dynorphin-(1-13) is a potent in vivo suppressor of vasopressin levels in the rat. Acta Endocrinol. 114:1987;96-101.
52. Heinricher M.M., McGaraughty S., Grandy D.K. Circuitry underlying antiopioid actions of orphanin FQ in the rostral ventromedial medulla. J Neurophysiol. 78:1997;3351-3358.
53. Helyes Z., Nemeth J., Pinter E., Szolcsanyi J. Inhibition by nociceptin of neurogenic inflammation and the release of SP and CGRP from sensory nerve terminals. Br J Pharmacol. 121:1997;613-615.
54. Houtani T., Nishi M., Takeshima H., Nukada T., Sugimoto T. Structure and regional distribution of nociceptin/orphanin FQ precursor. Biochem Biophys Res Commun. 219:1996;714-719.
55. Huidobro-Toro J.P., Huidobro F. Central effects of morphine, levorphanol, (-)-methadone, and the opioid-like peptides β-endorphin and D-alanine-methionine enkephalinamide on urine volume outflow and electrolytes. J Pharmacol Exp Ther. 217:1981;579-585.
56. + (GIRK) channel. Brain Res Mol Brain Res. 45:1997;117-126.
57. Inenanga K., Imura H., Yanaihara N., Yamashita H. κ-selective opioid-receptor agonists leumorphin and dynorphin inhibit supraoptic neurons in rat hypothalamic slice preparations. J Neuroendocrinol. 2:1990;389-395.
58. Kapusta D.R. Opioid mechanisms controlling renal function. Clin Exp Pharmacol Physiol. 22:1995;891-902.
59. 2 and orphanin FQ/Nociceptin (OFQ/N) produce similar cardiovascular and renal responses in conscious rats. J Pharmacol Exp Ther. 289:1999;173-180.
60. Kapusta D.R., Chang J.-K., Kenigs V.A. Central nociceptin produces biphasic changes in urine flow rate in conscious rats via ADH dependent and -independent mechanisms. FASEB J. 13:1999;A457.
61. Kapusta D.R., Kenigs V.A. Cardiovascular and renal responses produced by central orphanin FQ/nociceptin occur independent of renal nerves. Am J Physiol. 277:1999;R987-R995.
62. Kapusta D.R., Obih J.C. Central kappa opioid receptor-evoked changes in renal function in conscious rats participation of renal nerves . J Pharmacol Exp Ther. 267:1993;197-204.
63. Kapusta D.R., Obih J.C., DiBona G.F. Central μ-opioid receptor mediated changes in renal function in conscious rats. J Pharmacol Exp Ther. 265:1993;134-143.
64. Kapusta D.R., Sezen S.F., Chang J.-K., Lippton H., Kenigs V.A. Diuretic and antinatriuretic responses produced by the endogenous opioid-like peptide, nociceptin (orphanin FQ). Life Sci. 60:1997;PL15-PL21.
65. Kato M., Chapman C., Bicknell R.J. Activation of κ-opioid receptors inhibits depolarisation-evoked exocytosis but not the rise in intracellular in secretory nerve terminals of the neurohypophysis. Brain Res. 574:1992;138-146.
66. Knoflach F., Reinscheid R.K., Civelli O., Kemp J.A. Modulation of voltage-gated calcium channels by orphanin FQ in freshly dissociated hippocampal neurons. J Neurosci. 16:1996;6657-6664.
67. + channel in Xenopus oocytes. Br J Pharmacol. 120:1997;986-987.
68. Koepke J.P., DiBona G.F. Central adrenergic receptor control of renal function in conscious hypertensive rats. Hypertension. 8:1986;133-141.
69. Koepke J.P., Jones S., DiBona G.F. Sodium responsiveness of central α2-adrenergic receptors in spontaneously hypertensive rats. Hypertension. 11:1988;326-333.
70. Kopp U.C., DiBona G.F. The neural control of renal function. Seldin D.W., Giebisch. The kidney physiology and pathophysiology . 1992;1157-1204 Raven Press, New York.
71. Kummer W., Fischer A. Nociceptin and its receptor in guinea-pig sympathetic ganglia. Neurosci Lett. 234:1997;35-38.
72. Lai C.C., Wu S.Y., Chen C.-T., Dun N.J. Nociceptin inhibits rat sympathetic preganglionic neurons in situ and in vitro. Am J Physiol. 278:2000;R592-R597.
73. Lai C.C., Wu S.Y., Dun S.L., Dun N.J. Nociceptin-like immunoreactivity in the rat dorsal horn and inhibition of substantia gelatinosa neurons. Neuroscience. 81:1997;887-891.
74. Lecci A., Giuliani S., Tramontana M., Criscuoli M., Maggi C.A. Multiple sites of action in the inhibitory effect of nociceptin on micturation reflex. J Urol. 163:2000;638-645.
75. Leander J.D. A kappa opioid effect increased urination in the rat . J Pharmacol Exp Ther. 224:1983;89-94.
76. Leander J.D., Zerbe R.L., Hart J.C. Diuresis and suppression of vasopressin by kappa opioids comparison with mu and delta opioids and clonidine . J Pharmacol Exp Ther. 234:1985;463-469.
77. Liebel J.T., Swandulla D., Zeilhofer H.U. Modulation of excitatory synaptic transmission by nociceptin in superficial dorsal horn neurons of the neonatal rat spinal cord. Br J Pharmacol. 121:1997;425-432.
78. Lin B., Waterman R., Lippton H. Nociceptin receptor activation produces nitric oxide-mediated systemic hypotension. Life Sci. 6:2000;PL99-PL104.
79. + currents in hippocampal CA1 neurons by both ORL-1 and opiate receptor mechanisms. J Neurophysiol. 82:1999;1776-1785.
80. Madeddu P., Salis M.B., Milia A.F., et al. Cardiovascular effects of nociceptin in unanesthetized mice. Hypertension. 33:1999;914-919.
81. Maggi C.A. The role of peptides in the regulation of the micturation reflex an update . Gen Pharmacol. 22:1991;1-24.
82. Makman M.H., Lyman W.D., Dvorkin B. Presence and characterization of nociceptin (orphanin FQ) receptor binding in adult rat and human fetal hypothalamus. Brain Res. 762:1997;247-250.
83. McFadzean I. The ionic mechanisms underlying opioid actions. Neuropeptides. 11:1988;173-180.
84. Meis S., Pape H.C. Postsynaptic mechanisms underlying responsiveness of amygdaloid neurons to nociceptin/orphanin FQ. J Neurosci. 18:1998;8133-8144.
85. 1 receptor. Nature (London) 1995;377:12:532-5.
86. Mollereau C., Parmentier M., Mailleux P., et al. ORL-1, a novel member of the opioid receptor family Cloning, functional expression and localization . FEBS Lett. 341:1994;33-38.
87. Mollereau C., Simons M.J., Soularue P., et al. Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene. Proc Natl Acad Sci USA. 93:1996;8666-8670.
88. Murphy N.P., Ly H.T., Maidment N.T. Intracerebroventricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats. Neuroscience. 75:1996;1-4.
89. Neal C.R., Mansour A., Reinscheid R., Nothacker H.-P., Civelli O., Watson S.J. Localization of orphanin FQ (Nociceptin) peptide and messenger RNA in the central nervous system of the rat. J Comp Neurol. 406:1999;503-547.
90. + evoked glutamate release from rat cortical slices. Br J Pharmacol. 119:1996;1081-1083.
91. Nothacker H.P., Reinscheid R.K., Mansour A., et al. Primary structure and tissue distribution of the orphanin FQ precursor. Proc Natl Acad Sci USA. 93:1996;8677-8682.
92. Oiso Y., Iwasaki Y., Kondo K., Takatsuki K., Tomita A. Effect of the opioid κ-receptor agonist U50488H on the secretion of arginine vasopressin. Neuroendocrinology. 48:1988;658-662.
93. Olson GA, Olson RD, Vaccarino AL, Kastin AJ. Endogenous opiates. Peptides 1998;1997:19:1791-843.
94. Ozaki S., Kawamoto H., Itoh Y., Miyaji M., Iwasawa Y., Ohta H. A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORL1) antagonist J-113397 . Eur J Pharmacol. 2000;R17-R18.
95. Patel H.J., Giembycz M.A., Spicuzza L., Barnes P.J., Belvisi M.G. Naloxone insensitive inhibition of acetylcholine release from parasympathetic nerves innervating guinea pig trachea by the novel opioid, nociceptin. Br J Pharmacol. 120:1997;735-736.
96. Pechnick R.N. Effects of opioids on the hypothalamo-pituitary-adrenal axis. Annu Rev Pharmacol Toxicol. 32:1993;353-382.
97. Pfeiffer A., Braunn S., Mann K., Meyer H.-D., Brantl V. Anterior pituitary hormone responses to a κ-opioid agonist in man. J Clin Endocrinol Metab. 62:1986;181-185.
98. 1-17-containing peptide produced in the rodent and monkey hypothalamus. Peptides. 19:1998;133-139.
99. Reece P.A., Sedman A.J., Rose S., Wright D.S., Dawkins R., Rajagopalan R. Diuretic effects, pharmacokinetics, and safety of a new centrally acting κ-opioid agonist (CI-977) in humans. J Clin Pharmacol. 34:1994;1126-1132.
100. Reinscheid R.K., Nothacker H.P., Bourson A., et al. Orphanin FQ a neuropeptide that activates an opioid-like G protein-coupled receptor . Science. 270:1995;792-794.
101. Rimoy G.H., Bhaskar N.K., Wright D.M., Rubin P.C. Mechanism of diuretic action of spiradoline (U-62066E) a kappa opioid receptor agonist in the human. Br J Pharmacol. 32:1991;611-615.
102. Rossi N.F. The mechanisms of κ-opioid agonist-induced water diuresis central vs. peripheral actions . Saito T., Kurokawa K., Yoshida S. Neurohypophysis recent progress of vasopressin and oxytocin research . 1995;289-299 Elsevier Science, London.
103. Rossi N.F., Brooks D.P. κ-opioid agonists BRL 52656 inhibition of osmotically stimulated vasopressin secretion preferential action at hypothalamic sites . Am J Physiol. 270:1996;E367-E372.
104. Schlicker E., Werthwein S., Kathmann M., Bauer U. Nociceptin inhibits noradrenaline release in the mouse brain cortex via presynaptic ORL1 receptors. Naunyn-Schmiedeberg's Arch Pharmacol. 358:1998;418-422.
105. Shirasaka T., Kunitake T., Kato K., Takasaki M., Kannan H. Nociceptin modulates renal sympathetic nerve activity through a central action in conscious rats. Am J Physiol. 277:1999;R1025-R1032.
106. Shu Y.-S., Zhao Z.-Q., Li M.-Y., Zhou G.-M. Orphanin FQ/nociceptin modulates glutamate- and kainic acid-induced currents in acutely isolated rat spinal dorsal horn neurons. Neuropeptides. 32:1998;567-571.
107. + conductance by orphanin-FQ/nociceptin in vasopressin-containing neurons. Neuroendocrinology. 69:1999;385-396.
108. Stanfa L.C., Chapman V., Kerr N., Dickenson A.H. Inhibitory action of nociceptin on spinal dorsal horn neurons of the rat, in vivo. Br J Pharmacol. 118:1996;1875-1877.
109. Van Wimersma Greidanus T.B., van de Heijning B.J.M. Opioid control of vasopressin and oxytocin release. Regul Pept. 45:1993;183-186.
110. Van Zwieten P.A. Centrally acting antihypertensive drugs. Present and future. Clin Exp Hypertens. 21:1999;859-873.
111. + conductance in dorsal raphe nucleus neurons. Br J Pharmacol. 117:1996;1609-1611.
112. Vaughan C.W., Ingram S.L., Christie M.J. Actions of the ORL1 receptor ligand nociceptin on membrane properties of rat periaqueductal gray neurons in vitro. J Neurosci. 17:1997;996-1003.
113. Verbalis J.G., Mangione M.P., Stricker E.M. Oxytocin produces natriuresis in rats at physiological plasma concentrations. Endocrinology. 128:1991;1317-1322.
114. + conductance. Neuroendocrinology. 67:1998;73-82.
115. Wang J.B., Johnson P.S., Imay Y., et al. cDNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Lett. 348:1994;75-79.
116. Wang X.M., Zhang K.M., Mokha S.S. Nociceptin (orphanin FQ), an endogenous ligand for the ORL1 (opioid-receptor-like 1) receptor; modulates responses of trigeminal neurons evoked by excitatory amino acids and somatosensory stimuli. J Neurophysiol. 76:1996;3568-3572.
117. Yakimova K.S. , Pierau Fr-K. Nociceptin/Orphanin FQ. Effects on thermoregulation in rats. Meth Find Exp Clin Pharmacol. 21:1999;345-352.
118. 2 on tonic activity of rat hypothalamic neurons. Neuroscience. 274:1999;87-90.
119. Yazdani A., Takahashi T., Bagnol D., Watson S.J., Owyang C. Functional significance of a newly discovered neuropeptide orphanin FQ, in rat gastrointestinal motility. Gastroenterology. 116:1999;108-117.
120. Yu T.P., Fein J., Phan T., Evans C.J., Xie C.W. Orphanin FQ inhibits synaptic transmission and long-term potentiation in rat hippocampus. Hippocampus. 7:1997;88-94.
121. Zhao B.G., Chapman C., Bicknell R.J. Opioid-noradrenergic interactions in the neurophysis. I. Differential opioid receptor regulation of oxytocin, vasopressin, and noradrenaline release. Neuroendocrinology. 48:1988;16-24.